Overview

Study Evaluating ERB-041 in Active Crohn's Disease

Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
Evaluate the response of inflammatory serum markers to oral ERB-041 in subjects with inflammation associated with active Crohn's disease.
Phase:
Phase 1
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer